CHRS

Coherus Oncology, Inc. NASDAQ

Healthcare ·Biotechnology ·US · coherus.com

$1.79

Mkt Cap $209.7M

52w Low $0.71 56.7% of range 52w High $2.62

50d MA $1.73 200d MA $1.52

P/E (TTM) -1.2x

EV/EBITDA -0.7x

P/B 3.5x

Debt/Equity 0.7x

ROE 275.4%

P/FCF -1.2x

RSI (14) —

ATR (14) —

Beta 1.04

50d MA $1.73

200d MA $1.52

Avg Volume 1.5M

About

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 9, 2026	AMC	-0.36	-0.34	+4.3%	1.93	-3.6%	+1.0%	-7.8%	-12.4%	-15.5%	-14.0%	—
Nov 6, 2025	AMC	-0.32	-0.33	-3.1%	1.49	-9.4%	-10.1%	-15.4%	-9.4%	-8.7%	-15.4%	—
Aug 7, 2025	AMC	-0.31	-0.34	-9.7%	0.88	-1.1%	-7.1%	-0.4%	+3.6%	+13.0%	+15.4%	—
May 12, 2025	AMC	-0.31	-0.35	-12.9%	1.02	-14.0%	-19.1%	-22.5%	-24.7%	-25.4%	-21.6%	—
Mar 10, 2025	AMC	-0.10	-0.28	-180.0%	1.04	+0.0%	+1.0%	-5.8%	-14.4%	-11.5%	-12.0%	—
Nov 6, 2024	AMC	-0.10	-0.01	+90.0%	0.72	+10.0%	+13.3%	+12.6%	+7.6%	+13.8%	+7.6%	—
Aug 8, 2024	AMC	-0.21	-0.14	+33.3%	1.29	+12.4%	+10.9%	+13.2%	+11.6%	+6.2%	+20.2%	—
May 9, 2024	AMC	-0.05	-0.32	-540.0%	2.12	+2.4%	-10.4%	-1.4%	-1.9%	+2.8%	+2.4%	—
Mar 13, 2024	AMC	-0.21	-0.62	-195.2%	2.30	-8.7%	-5.7%	-3.5%	-3.5%	+6.5%	+7.8%	—
Nov 6, 2023	AMC	-0.21	-0.27	-28.6%	3.54	-22.6%	-30.2%	-42.7%	-54.8%	-55.1%	-51.4%	—
Aug 2, 2023	AMC	-0.52	-0.38	+26.9%	4.34	+9.4%	+17.7%	+16.8%	+15.7%	+10.4%	+5.8%	—
May 8, 2023	AMC	-0.61	-0.75	-23.0%	8.14	-20.6%	-27.4%	-27.4%	-36.2%	-39.8%	-39.9%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Sep 4	Maxim Group	Upgrade	Hold → Buy	—	$1.26	$1.31	+4.0%	+4.0%	+2.4%	+8.7%	+7.1%	+4.0%
Apr 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.03	$1.00	-2.9%	-3.0%	+0.0%	+1.9%	+6.8%	-1.0%
Apr 24	UBS	Maintains	Neutral → Neutral	—	$1.11	$1.09	-1.8%	-9.0%	-7.2%	-7.2%	-9.9%	-7.2%
Mar 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.04	$1.04	+0.0%	+1.0%	-5.8%	-14.4%	-11.5%	-12.0%
Jan 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.31	$1.33	+1.5%	-2.3%	-5.3%	-11.5%	-15.3%	-6.9%
Jan 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.32	$1.35	+2.3%	-0.8%	-3.0%	-6.1%	-12.1%	-15.9%
Dec 5	Baird	Maintains	Outperform → Outperform	—	$1.71	$1.80	+5.3%	-11.7%	-0.6%	-0.6%	-5.8%	-3.5%
Dec 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.71	$1.82	+6.4%	+0.0%	-11.7%	-0.6%	-0.6%	-5.8%
Nov 8	Baird	Maintains	Outperform → Outperform	—	$0.82	$0.83	+1.2%	-0.6%	-5.0%	+0.4%	-5.0%	-5.8%
Nov 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.72	$0.80	+10.0%	+13.3%	+12.6%	+7.6%	+13.8%	+7.6%
Sep 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.30	$1.32	+1.5%	-19.2%	-20.0%	-19.2%	-13.1%	-21.5%
Aug 16	UBS	Downgrade	Buy → Neutral	—	$1.55	$1.46	-5.8%	-18.7%	-18.7%	-19.4%	-13.5%	-14.8%
Aug 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.35	$1.25	-7.4%	-2.2%	-1.5%	-8.1%	-4.4%	+5.9%
Jul 1	Baird	Maintains	Outperform → Outperform	—	$1.73	$1.73	+0.0%	-6.9%	-19.7%	-19.7%	-23.1%	-26.6%
May 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.01	$2.03	+1.0%	-5.0%	-6.5%	-8.5%	-6.5%	-9.5%
May 13	Truist	Maintains	Buy → Buy	—	$1.90	$1.92	+1.1%	+10.0%	+9.5%	+14.7%	+14.2%	+11.6%
May 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.12	$2.17	+2.4%	-10.4%	-1.4%	-1.9%	+2.8%	+2.4%
Mar 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.45	$2.40	-2.0%	+1.2%	+2.4%	-4.9%	-6.9%	-6.1%
Mar 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.30	$2.10	-8.7%	-5.7%	-3.5%	-3.5%	+6.5%	+7.8%
Jan 23	Baird	Maintains	Outperform → Outperform	—	$2.58	$2.60	+0.8%	-7.0%	-10.9%	-8.1%	-9.3%	-10.9%
Jan 23	Truist	Maintains	Buy → Buy	—	$2.58	$2.60	+0.8%	-7.0%	-10.9%	-8.1%	-9.3%	-10.9%
Dec 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.18	$3.00	+37.6%	+23.4%	+48.6%	+52.8%	+44.0%	+38.5%
Dec 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.29	$2.30	+0.4%	+0.4%	-3.1%	-7.9%	-8.7%	+3.5%
Nov 28	Truist	Maintains	Buy → Buy	—	$1.94	$1.91	-1.5%	+8.8%	+12.4%	+9.8%	+18.6%	+18.6%
Nov 8	Maxim Group	Downgrade	Buy → Hold	—	$2.47	$2.48	+0.4%	-17.8%	-35.2%	-35.6%	-30.4%	-26.3%
Nov 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.54	$2.74	-22.6%	-30.2%	-42.7%	-54.8%	-55.1%	-51.4%
Oct 23	Barclays	Maintains	Overweight → Overweight	—	$3.54	$3.48	-1.7%	-10.0%	-7.6%	-17.9%	-22.6%	-25.4%
Sep 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.05	$4.00	-1.2%	-1.7%	-2.0%	-4.4%	-7.7%	-11.1%
Sep 26	Truist	Maintains	Buy → Buy	—	$4.05	$4.00	-1.2%	-1.7%	-2.0%	-4.4%	-7.7%	-11.1%
Aug 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.34	$4.75	+9.4%	+17.7%	+16.8%	+15.7%	+10.4%	+5.8%
Jul 14	Truist	Maintains	Buy → Buy	—	$4.27	$4.33	+1.4%	-4.9%	+2.3%	+2.8%	+2.6%	-2.3%
Jun 28	Truist	Maintains	Buy → Buy	—	$3.84	$3.84	+0.0%	+5.5%	+9.1%	+11.2%	+15.1%	+19.0%
Jun 20	Truist	Maintains	Buy → Buy	—	$4.13	$4.17	+1.0%	-7.0%	-6.3%	-8.2%	-3.4%	-7.7%
Jun 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.13	$4.17	+1.0%	-7.0%	-6.3%	-8.2%	-3.4%	-7.7%
Jun 15	Truist	Maintains	Buy → Buy	—	$5.36	$5.36	+0.0%	+0.6%	-22.9%	-28.4%	-27.8%	-29.3%
Jun 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.98	$5.00	+0.4%	+5.8%	+8.0%	+8.2%	+8.8%	+8.0%
Jun 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.09	$4.17	+2.0%	-1.0%	+8.8%	+21.8%	+28.9%	+31.5%
May 23	Barclays	Maintains	Overweight → Overweight	—	$4.46	$4.46	+0.0%	+2.2%	-2.7%	-3.8%	-2.5%	-7.0%
May 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.14	$6.46	-20.6%	-27.4%	-27.4%	-36.2%	-39.8%	-39.9%
May 1	Truist	Maintains	Buy → Buy	—	$7.23	$7.49	+3.6%	+6.1%	-0.8%	+1.0%	+1.2%	+2.1%
Mar 28	UBS	Upgrade	Neutral → Buy	—	$6.00	$6.34	+5.7%	+7.0%	+8.0%	+7.2%	+14.0%	+24.7%
Mar 8	Barclays	Maintains	Overweight → Overweight	—	$7.30	$7.25	-0.7%	-5.5%	-14.5%	-16.8%	-12.7%	-13.0%
Mar 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.77	$6.53	-3.5%	+7.8%	+1.9%	-7.8%	-10.3%	-5.9%
Nov 16	Mizuho	Maintains	Buy → Buy	—	$7.96	$7.88	-1.0%	-7.7%	-15.7%	-15.3%	-17.1%	-17.7%
Nov 14	JP Morgan	Maintains	Neutral → Neutral	—	$7.79	$7.72	-0.9%	+1.9%	+2.2%	-5.6%	-13.9%	-13.5%
Aug 16	Mizuho	Maintains	Buy → Buy	—	$13.87	$14.03	+1.2%	-3.5%	-5.7%	-6.3%	-8.8%	-11.2%
Jun 14	UBS	Maintains	Neutral → Neutral	—	$6.19	$6.28	+1.5%	-3.1%	-3.2%	-5.3%	+1.8%	+7.3%
May 20	Mizuho	Maintains	Buy → Buy	—	$7.91	$7.97	+0.8%	+5.1%	+1.0%	-3.0%	-6.3%	-3.2%
May 9	Barclays	Maintains	Overweight → Overweight	—	$8.43	$8.10	-3.9%	-4.7%	+1.1%	-8.1%	-10.0%	-5.7%
Mar 7	JP Morgan	Downgrade	Overweight → Neutral	—	$11.85	$11.49	-3.0%	-2.0%	-3.5%	+2.7%	+4.9%	+4.1%

Recent Filings

8-K

Coherus Oncology, Inc. -- 8-K Filing

Coherus Oncology doubled 2025 revenue to $40.8 million while slashing debt by 90% to $38.8 million, strengthening its balance sheet with $172.1 million in cash, indicating improved financial stability for investors.

Mar 9

8-K · 8.01 !! High

Coherus Oncology, Inc. -- 8-K 8.01: Material Event / Announcement

Coherus Oncology agreed to issue 28.6 million common shares to underwriters in a public offering, with underwriters granted a 30-day option to purchase additional shares.

Feb 17

8-K · 8.01 !! High

Coherus Oncology, Inc. -- 8-K 8.01: Material Event / Announcement

Coherus disclosed a material event that likely impacts near-term stock momentum; investors should monitor the announcement details for potential effects on clinical programs, partnerships, or financial guidance that could influence valuation.

Feb 4

Data updated apr 25, 2026 1:17am · Source: massive.com